How about Hongri Pharmaceutical, the prospect of Hongri Pharmaceutical

Enter a long shipping period.

The prospects of Hongri Pharmaceutical are as follows:

1) Since the end of 2019, Hongri Pharmaceutical's drug sales have entered a new era, with the publication of the "Randomized Controlled Multicenter Clinical Study on the Efficacy of Xuebijing Injection on Severe Community-Acquired Pneumonia" published in the journal "Critical Care Medicine", as well as the negotiation into the national medical insurance catalog, it will bring new opportunities for the future sales of the flagship product Xuebijing Injection, and the company will continue to promote the academic research of Xuebijing Injection and explore the clinical value of the product. The next few years will be the period of concentrated advent of the company's R&D achievements, such as moxifloxacin hydrochloride sodium chloride injection, ibandronate sodium, PTS, KB, etc., the company will focus on the ICU field to create leading products, continue to reserve high-quality products, realize product landing, and further enrich the product structure.

2) Hongri Pharmaceutical's formula granules will continue to carry out research on national quality standards, accelerate the development and implementation of medicinal and edible homologous products, and strengthen and improve the construction of the R&D system of formula granules. Combined with the location advantages of authentic medicinal materials and the layout of the production area, we will strengthen the centralized procurement ability and strive to obtain a more competitive cost advantage. Relying on the traceability technology of authentic medicinal materials and loading products, and with the help of infrared fingerprint detection, we will build high-quality brands and expand the sales scale of traditional Chinese medicine decoction pieces; With the help of TCM doctor resources and TCM intelligent diagnosis and treatment, improve the coverage of the primary healthcare market; The medical and health service business will continue to upgrade and iterate the online platform, continuously improve the fully collaborative medical service and the value transformation platform of traditional Chinese medicine doctors, and form a terminal brand channel for the Group's big health products.

Close to the terminal needs of the market, integrate the products, channels, smart medical and other self-owned resources of the whole industry chain of formula granules, establish a traditional Chinese medicine business group, and make use of the company's resource advantages to strengthen the brand synergy.

3) The medical device business focuses on the family medical market, focuses on the domestic primary medical market, deeply cultivates the international market, integrates domestic and foreign resources to enrich the product line, and improves brand recognition.

4) Give full play to the advantages of resource sharing of the raw materials division, create high-end varieties through multiple channels, improve technical marketing capabilities, enter the international market, and expand the application of products in the non-pharmaceutical field.

Generally, there are more **, and the dealer's chips are not enough to protect the pants. However, Hongri Pharmaceutical is also considered a dark horse stock of low-valued medical technology. Here's why:

1.Advantages of high-tech biomedical industry. The company has the core science and technology of Huyanyan in the three high-tech fields of traditional Chinese medicine, chemical medicine and high-end medical equipment, and is in the emerging industry of Guoda Mengjia.

China's 13th Five-Year Plan intends to increase the output value of the industry from 3 6 trillion yuan to 8 trillion yuan. This year, the World Association of Chinese Medicine Branch Presidents Conference was held in China, which will promote the global development of Chinese medicine and usher in a new opportunity for the development of Chinese medicine.

2.The company's base has been reversed. At present, it has developed into a high-tech pharmaceutical and health industry cluster integrating investment and financing, R&D, production and sales across many fields such as modern Chinese medicine, chemical medicine, biotechnology medicine, pharmaceutical excipients and APIs, medical devices, medical and health services.

The company has completed a major restructuring, and the company's restructuring has always been the subject of large fluctuations, but Hongri Pharmaceutical not only did not rise but stagnation, and there may be a late reaction. Since the beginning of this year, the company has announced a number of new drugs for coronary heart disease, which have high scientific and technological content, high added value and wide application. Cardiovascular disease is currently the main killer of human death and health, and cardiovascular disease and cancer are the first and second causes of human death, accounting for about 40 and 36 respectively.

The company produces a variety of drugs for cardiovascular diseases, and the prospects are great.

The low share price of Hongri Pharmaceutical is due to the loss of the balance.

A market is a place for the transfer, sale, and circulation of issues that have been issued, including exchange markets and over-the-counter markets.

The two high judgments are cautious and the categories are large. Since it is built on the distribution market.

Therefore, it is also called the secondary market. ** The structure of the market and the trading activity are more than the issuing market (primary market.

The more complex, the more important and influential.

The market is a place for issuance and trading, including two parts: the issuance market and the circulation market. The joint-stock company quickly concentrates a large amount of funds through the issuance of ** to the society to achieve large-scale operation of production; The surplus of the socially dispersed relatives invest in joint-stock companies in line with the principle of "benefit sharing and risk sharing" to seek wealth appreciation.

A transaction is a buying and selling. There are two main forms of trading, one is through an exchange.

Buying and selling**, known as floor trading; The other is not traded through an exchange, which is called over-the-counter trading.

Summary. Hello dear dear, hello and happy to <>< you this question

What is the investment situation of Hongri Pharmaceutical: Hongri Pharmaceutical: The company's quality is good, the market value is seriously overestimated, the company's comprehensive quality is average, the value investment index is low, there are more negatives, and the support is weak.

How is the investment situation of Hongri Pharmaceutical.

Hello pro kai stupid high pro, hello hello am happy to <>< for your question

What is the investment situation of Hongri Pharmaceutical: Hongri Pharmaceutical: The company's quality is good, the market value is seriously overestimated, the company's comprehensive quality is average, the value investment index is low, there are more negatives, and the support is weak.

What is the investment situation of Hongri Pharmaceutical: According to the news of China.com, it has recently been reported that Hongri Pharmaceutical has a major investment project, involving hundreds of millions of yuan, and claims that the investment is mainly in the traditional Chinese medicine granule preparation industry. To this end, we made relevant inquiries to the relevant personnel of Hongri Pharmaceutical.

A relevant person from Hongri Pharmaceutical said that the news on the Internet is true, and Hongri Pharmaceutical has indeed invested in the field of traditional Chinese medicine granules recently, and the investment amount will reach hundreds of millions of yuan. The investment will further strengthen the company's development in this field, continue to improve and strengthen the company's own industrial chain construction. It is reported that at present, Hongri Pharmaceutical has realized the integration of production control, optimization, scheduling, management and operation in the field of traditional Chinese medicine granules, and is improving the production, manufacturing and management level of the traditional Chinese medicine granule industry for the purpose of reducing operating costs, improving production efficiency, improving product quality and reducing resource and energy consumption.

According to the previous report, Hongri Pharmaceutical was founded in 1996, and its main business is currently divided into six major sectors: finished drugs, traditional Chinese medicine formula granules, raw and auxiliary materials, medical devices, medical and health services, and pharmaceutical and medical equipment chains. From the perspective of financial situation, in 2020, Hongri Pharmaceutical achieved operating income of 100 million yuan, a year-on-year increase; The net profit was 100 million yuan, a year-on-year increase. In the first quarter of this year, the public stool hunger division achieved operating income of 100 million yuan, a year-on-year increase; The net profit was 100 million yuan, a year-on-year increase.

The data shows that the traditional Chinese medicine formula granules business of Hongri Pharmaceutical will achieve operating income of 100 million yuan in 2020, accounting for an increase in the proportion of total revenue compared with 2019. According to reports, at present, there are more than 600 kinds of Kangrentang traditional Chinese medicine formula granule products, basically covering all varieties with the highest clinical use frequency of traditional Chinese medicine. A total of more than 120 Chinese herbal medicine planting bases have been built nationwide, involving 110 varieties.

A whole-process traceability system has been established to realize the traceability of all varieties of formula granules.

Summary. Hello, Hongri Pharmaceutical is seriously underestimated by the market Reasons: the good has not been determined for a long time; The capital chain of the major shareholder is broken,**; Lack of intervention of powerful institutions, ** obvious; **There is also no consensus on views and investment behavior.

As the dead bulls of Hongri Pharmaceutical, they are naturally deeply confused.

Hello, Hongri Pharmaceutical is seriously underestimated by the market for the reasons: the good has not been confirmed for a long time; The capital chain of the major shareholder is broken,**; Lack of strength to intervene in the town, and the ** is obvious; **There is also no consensus on views and investment behavior. As the dead bull of Hongri Pharmaceutical, Yu Leak is naturally deeply confused.

After the second round of intervention in July, there were several operations, and there were still reasons to stick to it in general. This post does not believe that the three major benefits (three major scientific and technological achievements) in the later stage of the red day medicine industry have all failed (failed), of course, technology stocks have both risks and opportunities.

At 5 45 yuan it was pointed out that it had been held into the area of low inhalation. However, this time, before taking the ** very low, I looked at the high line, and lost the opportunity to sell high, and the scoundrel had to increase his position on the dip.

The performance that can be determined from the three quarterly reports and annual reports**: the positive growth of the performance of the three quarterly reports becomes a reality; It is relatively certain that the annual report is expected to increase by more than 100.

Regarding the future trend of Hongri Pharmaceutical, now the global new crown patients continue to increase, the post-epidemic era is a long-term era, both the test kit and vaccine are short-term needs, only the new crown special drugs and severe patients Xuebiqing and Keguan No. 1 have a larger market, the United States belongs to the heavy attack disaster-bearing area, why can the second phase of clinical trial in the United States be given green channel approval, it must be the best clinical effect, plus the United States is in urgent need of this drug ** patients, it is estimated that the later light of the new crown ** market in the United States, According to the estimated procurement scale of the kit at 30 billion US dollars, I think the procurement scale of the new crown ** drug should be more than five times that of the kit, about 150 billion US dollars, in addition to the share of local pharmaceutical companies in the United States at two-thirds, the share of Hongri Pharmaceutical also has a share of 50 billion US dollars, the future of Hongri Pharmaceutical is not only the US market, the global market is dozens of times that of the US market, at that time the demand scale of Hongri Pharmaceutical is at least 300 billion US dollars, If this single Keguan No. 1 and Xuebiqing products are coupled with the country's vigorous support for the development of traditional Chinese medicine granules, the future of Hongri Pharmaceutical will be unattainable.